Skip to content
lifestyle.theroguemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Biodexa Pharmaceuticals PLC
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026
Interim results for the six months ended June 30, 2026
September 14, 2026
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
August 20, 2026
Result of General Meeting
July 29, 2026
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
July 29, 2026
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
June 29, 2026
Biodexa issues letter to Shareholders
May 24, 2026
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026
Preliminary Results for the Year Ended 31 December 2025
March 31, 2026
Preliminary Results for the Year Ended 31 December 2025
March 30, 2026
1
2
Next Page
→